Unmet Needs and Resistance Mechanisms in Patients With HR+, HER2- MBC Who Progress on 1L CDK4/6 Inhibitors in Combination With Endocrine Therapy
By
Lilly Medical Affairs
FEATURING
Wassim Mchayleh
By
Lilly Medical Affairs
FEATURING
Wassim Mchayleh
In this video, Dr. Wassim Mchayleh shares his insights on the unmet needs and challenges faced in HR+, HER2- MBC, including the emergence of resistance mechanisms to ET, either alone or in combination with CDK4/6i.
To access additional videos and download free resources, click here.
VV-OTHR-US-DEL-3129 © 2024 Lilly USA, LLC. All Rights Reserved.
Comments are disabled for this content.
